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Abstract. Deletions within chromosome 11q22-23, are consid-
ered among the most common chromosomal aberrations in 
chronic lymphocytic leukemia (CLL), and are associated with 
a poor outcome. In addition to the ataxia telangiectasia mutated 
(ATM) gene, the baculoviral IAP repeat-containing 3 (BIRC3) 
gene is also located in the region. BIRC3 encodes a negative regu-
lator of the non-canonical nuclear factor κ-light-chain-enhancer 
of activated B cells (NF-κB) protein. Disruption of BIRC3 is 
known to be restricted to CLL fludarabine‑refractory patients. 
The aim of the present study was to determine the frequency of 
copy number changes of BIRC3 and to assess its association with 
two known predictors of negative CLL outcome, ATM and tumor 
protein 53 (TP53) gene deletions. To evaluate the specificity of 
BIRC3 alterations to CLL, BIRC3 copy numbers were assessed 
in 117 CLL patients in addition to 45 B-cell acute lymphocytic 
leukemia (B-ALL) patients. A commercially available multi-
plex ligation dependent probe amplification kit, which includes 
four probes for the detection of TP53 and four probes for ATM 
gene region, was applied. Interphase‑directed fluorescence in situ 
hybridization was used to apply commercially available probes 
for BIRC3, ATM and TP53. High resolution array-comparative 
genomic hybridization was conducted in selected cases. Genetic 
abnormalities of BIRC3 were detected in 23/117 (~20%) of CLL 
and 2/45 (~4%) of B-ALL cases. Overall, 20 patients with CLL 
and 1 with B-ALL possessed a BIRC3 deletion, whilst 3 patients 
with CLL and 1 with B-ALL harbored a BIRC3 duplication. All 
patients with an ATM deletion also carried a BIRC3 deletion. 
Only 2 CLL cases possessed deletions in BIRC3, ATM and TP53 
simultaneously. Evidently, the deletion or duplication of BIRC3 
may be observed rarely in B-ALL patients. BIRC3 duplication 
may occur in CLL patients, for which the prognosis requires addi-
tional studies in the future. The likelihood that TP53 deletions 
occur simultaneously with BIRC3 and/or ATM aberrations is low. 
However, as ATM deletions may, but not always, associate with 
BIRC3 deletions, each region should be considered in the future 
diagnostics of CLL in order to aid treatment decisions, notably 
whether to treat with or without fludarabine.
Introduction
Chronic lymphocytic leukemia (CLL) is the most common 
type of leukemia observed in people aged >50 years in Western 
countries. CLL is characterized by a heterogeneous clinical 
course, with a time to progression ranging from months to 
decades (1). The presence of cytogenetic abnormalities is a 
hallmark of CLL. The most common recurrent aberrations in 
CLL affect chromosomes 11q, 13q, 14q, 17p and the whole of 
chromosome 12. Certain abnormalities, including deletions 
in 11q22.3, the ataxia telangiectasia mutated (ATM) gene 
(10-20% of all CLL cases), and 17p13.1, the tumor protein 53 
(TP53) gene (5-10% of all CLL cases), are associated with a 
poor clinical outcome. Therefore, the detection of these aber-
rations is important for identifying high-risk patients, who 
suffer from rapid disease progression and a decreased overall 
survival time (2). Other frequent chromosomal aberrations 
in CLL are associated with a good (deletions in 13q14 or 
14q32.33) or intermediate (trisomy 12) prognosis (1,3-5).
CLL is considered to be an insidious disease. Certain CLL 
patients, particularly patients with a good prognosis, survive 
for several years without requiring treatment; however, another 
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subgroup of patients experience an aggressive disease course and 
have a short life expectancy, despite aggressive treatment (6). 
The latter group tends to exhibit a particular lack of response 
to fludarabine‑based regimens, which are generally considered 
to be the first line of treatment for CLL (6). In a large fraction 
of these patients, the molecular basis of the aggressive clinical 
course remains unclear; however, in ~40% of patients, the molec-
ular basis is hypothesized to be due to TP53 disruption (7). In 
addition, activation of the nuclear factor κ-light-chain-enhancer 
of activated B cells (NF-κB) pathway is considered to be a 
mechanism of resistance to disease eradication (7).
From a clinical perspective, CLL cases may be divided into 
three major clinical phases: i) newly diagnosed CLL; ii) progres-
sive CLL; and iii) relapsed or fludarabine‑refractory CLL. TP53 
abnormalities are observed in 40‑50% of relapsed and fludara-
bine-refractory CLL cases and the deletion of 11q22-23 occurs in 
25-30% of relapsed or fludarabine‑refractory CLL patients (8). 
In a large previous study, 637 patients were classified into 
four risk groups according to a multivariate analysis of overall 
survival, which was based on genomic abnormalities and the 
mutational status of TP53, baculoviral IAP repeat-containing 3 
(BIRC3), translocation-associated notch homolog 1 and splicing 
factor 3B subunit 1. Notably, the high-risk group was composed 
of patients that exhibited disruption to TP53 and/or BIRC3 (9).
In CLL, deletions within the long arm of chromosome 11 
may be highly variable in size. The deletion may be distin-
guished as the more common ‘classical or large deletion’ or 
an ‘atypical or small deletion’, which is uncommon and more 
frequently associated with ATM mutations. This variation indi-
cates that other genes may contribute to the pathobiology of 11q 
deletions in CLL, and one of the genes that is hypothesized to 
be involved is BIRC3 (10). BIRC3 disruption, mutations or dele-
tions are rarely detected in CLL at diagnosis (4% of patients), 
but are detected in 24% of fludarabine‑refractory CLL patients. 
In a previous study, fludarabine‑sensitive patients did not exhibit 
BIRC3 mutations initially, which suggests that BIRC3 disruption 
may be specifically associated with a chemo‑refractory CLL 
subtype (7). Therefore, BIRC3 disruption may be added to the 
panel of cytogenetic abnormalities, as it may be helpful in the 
early identification of relapsed and fludarabine‑refractory CLL 
patients. Affected patients should be considered for other treat-
ment regimens, including cyclin-dependent kinase inhibitor, 
Bruton's tyrosine-kinase inhibitor, B-cell lymphoma 2 inhibitor 
or and alemtuzumab/corticosteroids (8,10). BIRC3 abnormali-
ties provide a molecular rationale for using NF-κB inhibitors, 
which remain under development (7).
Materials and methods
Patients and sample preparation. The present study included 
117 CLL patients, and 45 B-cell acute lymphocytic leukemia 
(B-ALL) patients that were diagnosed according to standard 
criteria (11). The samples were obtained with the informed 
consent from the corresponding patients and according to the 
institutional Ethical Committee guidelines. For CLL cases, 
DNA was extracted from lymphocytes using the Gentra® Pure-
gene® Blood kit (Qiagen, Hilden, Germany), according to the 
manufacturer's protocol. For B-ALL cases, DNA was derived 
from cytogenetically prepared cells, as previously described (2), 
which were fixed in methanol/acetic acid (dilution, 3:1) (Table I).
Interphase fluorescence in situ hybridization (iFISH) analysis. 
iFISH analyses were performed as previously described (2), 
using the following commercially available probes: LSI 
p53/LSI ATM (in 17p13.1 and 11q22.3), CEP 3 (D3Z1 in 
3p11.1-q11.1), CEP 4 (D4Z1 in 4p11-q11), CEP 7 (D7Z1 in 
7p11.1-q11.1), CEP 11 (D11Z1 in 11p11.11-q11), CEP 16 (D16Z2 
in 16p11.1-q11.1), CEP 17 (D17Z1 in 17p11.1-q11.1) and CEP 18 
(D18Z1 in 18p11.1-q11.1), all from Vysis (Abbott GmbH & 
Company, KG, Wiesbaden, Germany); and ZytoLight® SPEC 
BIRC3/MALT1 DualColor Dual Fusion probe (in 11q22.2 and 
18q21.32) from ZytoVision GmbH (Bremerhaven, Germany). 
For each iFISH analysis, 100-200 interphase nuclei were 
examined per patient and probe.
Multiplex ligation‑dependent probe amplification (MLPA) 
analysis. MLPA was performed using the SALSA MLPA 
probemix P377-A1 for Hematological Malignancies kit 
(MRC-Holland, Amsterdam, Netherlands). The P377-A1 
probemix kit contains 52 probes for 37 genes. The TP53 
and ATM genes were assessed by four probes each; however, 
probes for the BIRC3 gene were not included in the kit (2). 
MLPA was successfully performed on 85/117 CLL samples 
and 32/45 B-ALL samples. MLPA was not successful for the 
remaining samples due to fragmentation of DNA.
Array‑comparative genomic hybridization (aCGH). aCGH 
was performed using the Agilent SurePrint G3 Human Genome 
Microarray 180 K (Agilent Technologies, Santa Clara, CA, 
USA), as previously described (12). aCGH was applied in a 
total of 3 CLL patients that carried a BIRC3 duplication and in 
1 B-ALL patient that possessed a BIRC3 deletion.
Results
Gene copy numbers. BIRC3 gene copy number variations were 
detected in 23/117 (~20%) of CLL and 2/45 (~4%) of B-ALL 
cases, as summarized and detailed in Fig. 1. BIRC3 deletions 
were identified in 20 cases of CLL (cases C‑1 to C‑20) and 
in 1 case of B-ALL (case A-1). ATM deletion was detected 
in the identical 20 CLL and 1 B-ALL cases. Therefore, all 
patients with a BIRC3 deletion also possessed an ATM dele-
tion. However, in cases C-1, C-8, C-10, C-13 and C-20 the 
detected clone sizes with deletions in BIRC3 and ATM were 
extremely varied from one another. In case C-1, the clone with 
the ATM deletion was 8x smaller compared with that with the 
BIRC3 deletion, whereas in cases C-8, C-10, C-13 and C-20, 
the clone with the BIRC3 deletion was 2-3x smaller than that 
with the ATM deletion. A BIRC3 duplication was identified in 
1 case of B-ALL (case A-2) and in 3 CLL patients (cases C-21 
to C-23) (Table II).
With regard to TP53 abnormalities, 3 patients with B-ALL 
possessed a TP53 deletion in the absence of any aberrations 
in BIRC3. TP53 deletions were present in 11 CLL patients, 
7 of which possessed no associated BIRC3 aberrations and, 
notably, 2 of which were accompanied by BIRC3 and ATM 
amplification.
BIRC3 duplication. In total, 3 CLL patients harbored a 
BIRC3 duplication (cases C-21 to C-23), 2 of which (C-21 and 
C-22) were accompanied by ATM and MALT1 duplications 
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Table I. Gender, age and cytogenetic results of the B-ALL and CLL cases used in the present study.
Case no. Gender Age, years DNA extracted from Cytogenetic results
A-1 Male 84 BM 46,XY, -9,t(9;22)(q34;q11),del(11)(q),+mar[cp3]/46,XY[5]
A-2 Male 23 BM Hyperdiploid/46,XY
A-3 Male 34 BM 46,XY
A-4 Male 19 BM 46,XY
A-5 Female 76 BM 45,X,-X[14]/46,XX[2]
C-1 Male 73 BM 46-47,XY,del(11)(q22q2?3),add(17)t(17;?)(p11.2;?)[cp5]/
    45-46,XY,del(11)(q22q2?3),del(17)(p11.2)[cp4]/
    43-46,XY,del(11)(q22q2?3)[cp2]/
    46,XY[7]
C-2 Female 50 B n.a.
C-3 Female 39 BM 43-46,XY,del(11)(q2?2q2?4)[cp5]/
    45-46,XY,del(11)(q2?2q2?4),del(15)(q1?1q2?3)[cp11]/
    46,XY[1]
C-4 Male 64 BM 46,XY
C-5 Male 43 BM 46,XY
C-6 Male 67 BM 46,XY
C-7 Male 77 BM 46,XY,del(11)(q?21),add(20)(p13)[7]/
    45,X,-Y[10]/ 46,XY[3]
C-8 Male 53 BM 46,XY
C-9 Male 59 BM n.a.
C-10 Male 73 BM 45,XY,der(2)t(2;13)(q?37;q?14),?del(6)(p?23),
    del(11)(q?21)der(12)t(12;13)(q?24;q?22),-13[cp4]/
    46,XY[19]
C-11 Male 72 B n.a.
C-12 Female 73 BM 46,XX,add(11)(q?22)[3]/ 46,XX[12]
C-13 Male 54 B 46,XY
C-14 Male 68 BM 46,XY
C-15 Male 53 BM 46,XY
C-16 Male 75 BM n.a.
C-17 Female 67 BM 46,XX[18]
    45,X,-X[1]
C-18 Male 74 BM n.a.
C-19 Male 65 BM 46,XY
C-20 Male 77 B 45-46,XY,del(11)(q?22q?23)[cp14]
    46,XY[5]
C-21 Male 83 BM 47,XY,-11,+12,+mar[cp3]/
    47,XY,del(5)(p1?3),-11,+12,-17,+mar1,+mar2[cp6]/
    46,XY[9]
C-22 Male 72 BM 46,XY
C-23 Male 59 B 46,XY
C-24 Female 66 B n.a.
C-25 Female 71 B 46,XX
C-26 Male 65 BM 46,XY,?t(3;?)(p21;?),add(17)(p?12)ort(17;?),-8,+mar[cp7]
    46,XY[9]
C-27 Female 74 B 46,XX
C-28 Female 74 BM 46,XX,i(17)(q10)[1]/ 46,XX,+12,i(17)(q10),-21[9]/
    46,XX,t(3;?)(q2?9;?)[4],-7[4],+12[4],i(17)(q10)[4][cp4]/
    46,XX[4]
C-29 Female 90 B n.a.
C-30 Male 56 BM n.a.
C-31 Female 65 BM 46,XX
A‑, B‑ALL case; C‑, CLL case; BM, cell pellet in Carnoys fixative from bone marrow; B, blood; n.a., data not available.
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in addition to TP53 deletion. To study these cases in greater 
depth, iFISH was performed using centrometric probes for 
chromosomes (CEP) 3, 4, 7, 11, 16 and 18. For these chromo-
somes, 3 signals were detected in 11% (case C-21) and 25% 
(case C-22) of the cells, and 4 signals were detected in 29% 
(case C-21) and 25% (C-22) of the cells, respectively (Fig. 2).
The third CLL case (C-23) with BIRC3 duplication was 
associated with normal copy numbers of TP53 and ATM; the 
Table II. Summary of MLPA and iFISH results of TP53, ATM, BIRC3 and MALT1 in all studied cases.
 TP53 (%) ATM (%) BIRC3 (%) MALT1 (%)
 ------------------------------------------------- --------------------------------------------------  
Case no. MLPA iFISH MLPA iFISH iFISH iFISH
A-1 N N D D (76.5) D (75.0) N
A-2 n.a. A (100.0) n.a. A (100.0) A (100.0) A (100.0)
A-3 D D (8.5) N N N N
A-4 D D (10.0) N N N N
A-5 D D (10.0) N N N N
A-6 to A-33 N N N N N N
A-34 to A-45 n.a. N n.a. N N N
C-1 D D (86.0) D D (11.0) D (80.0) N
C-2 D D (21.0) N D (23.0) D (22.0) N
C-3 N N D D (98.0) D (90.0) N
C-4 N N D D (23.5) D (30.0) N
C-5 N N D D (24.0) D (25.0) N
C-6 N N D D (88.0) D (85.0) N
C-7 N N D D (90.0) D (80.0) N
C-8 N N D D (77.0) D (50.0) N
C-9 N N D D (98.0) D (75.0) N
C-10 N N D D (87.0) D (60.0) N
C-11 N N D D (95.0) D (90.0) N
C-12 N N D D (83.0) D (80.0) N
C-13 N N D D (93.0) D (25.0) N
C-14 N N N D (33.0) D (15.0) N
C-15 N N N D (12.0) D (13.0) N
C-16 n.a. N n.a. D (80.0) D (78.0) N
C-17 n.a. N n.a. D (10.0) D (9.0) N
C-18 n.a. N n.a. D (73.0) D (64.0) N
C-19 n.a. N n.a. D (9.0) D (10.0) N
C-20 n.a. N n.a. D (96.0) D (42.0) N
C-21 D D (16.0) N A (50.0) A (50.0) A (50.0)
C-22 D D (40.0) N A (40.0) A (40.0) A (40.0)
C-23 N N N N A (36.0) N
C-24 D D (19.0) N N N N
C-25 D D (36.0) N N N N
C-26 D D (89.0) N N N N
C-27 D D (77.0) N N N N
C-28 D D (95.0) N N N N
C-29 N D (11.5) N N N N
C-30 n.a. D (86.5) n.a. N N N
C-31 N N N N N A (75.0)
C-32 to C-91 N N N N N N
C-92 to C-117 n.a. N n.a. N N N
Data are expressed as type of change to copy number (% of cells with aberration). TP53, tumor protein 53; ATM, ataxia telangiectasia mutated; 
BIRC3, baculoviral IAP repeat-containing 3; MALT1, mucosa-associated lymphoid tissue lymphoma translocation gene 1; MLPA, multiplex 
ligation‑dependent probe amplification; iFISH, interphase fluorescence in situ hybridization; A-, B-ALL case; C-, CLL case; N, no aberration; 
D, deletion; A, amplification; n.a., data not available.
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centromeric probes for chromosomes 11 and 17 only revealed 
2 signals each (Fig. 2).
Based on the aCGH results for cases C-21, C-22 and C-23, 
the TP53 deletion in C‑21 and C‑22 was confirmed; however, 
BIRC3 was normal in all 3 patients (Fig. 2). Therefore, 
cases C-21 and C-22 had a mixture of a malignant triploid 
and tetraploid cell clones and a deletion in TP53. Case C-23 
demonstrated the selective gain of copy numbers for BIRC3, 
without ATM involvement, in 36% of the cells; however, this 
finding was not detectable using aCGH.
MALT1 duplication. The patient with a MALT1 duplication 
(case C-31) possessed an acquired trisomy of chromosome 18, 
which was confirmed using MLPA and iFISH. The probes 
for the deleted in colorectal cancer gene on 18q21.2 and RNA 
(guanine-7-)methyltransferase gene on 18p11.22 revealed a 
duplication by MLPA, which was confirmed by iFISH in 75% 
of the cells.
B‑ALL patients. Regarding B-ALL patients, 1 case revealed a 
deletion in BIRC3 along with ATM (case A-1), and another case 
Figure 1. The distribution and of BIRC3, ATM and TP53 aberrations in CLL and B-ALL patients are summarized. (A) In CLL and B-ALL, the majority of 
patients did not show alterations in the three genes. Distribution of the loss and gain of copy numbers in the two patient groups is depicted. (B) Combinations of 
loss and gain of the three genes were identified in the patients with CLL and B‑ALL, with alterations from part (A). BIRC3, baculoviral IAP repeat-containing 3; 
ATM, ataxia telangiectasia mutated; TP53, tumor protein 53; CLL, chronic lymphocytic leukemia; B-ALL, B-cell acute lymphocytic leukemia.
  A   B
Figure 2. (A) Array comparative genomic hybridization confirmed the deletion in TP53, which was detected initially using iFISH and multiplex ligation 
dependent probe amplification for CLL cases C‑21 and C‑22. The whole short arm was deleted and the long arm was possibly duplicated due to an 
isochromosome 17 formation, at least in case C-21. (B) Examples for gain of copy numbers for BIRC3 and MALT1 in the 2 cases by iFISH: i) C-21, an 
example of 3 copies and ii) C-22, an example of 4 copies. (C) iFISH results of the CLL case C-23. BIRC3 had 3 copies in certain cells; however ATM, 
MALT1 and TP53 exhibited only 2 copies each, in all cells. TP53, tumor protein 53; CLL, chronic lymphocytic leukemia; iFISH, interphase fluorescence 
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was identified as possessing a triploid/hyperdiploid karyotype 
in the iFISH analysis using CEP 11, 17 and 18 (case A-2, result 
not shown), as was observed in the cases C-21 and C-22.
The BIRC3 deletion in B‑ALL case A‑1 was confirmed 
by aCGH, which reveled that the deletion in the long arm 
of chromosome 11 covered between chr11:67,773,863 and 
134,945,165 (GRCh37/hg19) (Fig. 3). The ATM and BIRC3 
genes are located between positions 102,188,181 and 
108,239,826.
Discussion
The BIRC3 gene, located on 11q22.2, is ~6 Mb centromeric to 
the ATM gene locus and is considered to be a negative regulator 
of the non-canonical NF-κB signaling pathway (13,14). BIRC3 
cooperates with tumor necrosis factor receptor-associated 
factors 2 and 3, in the same protein complex that negatively 
regulates the mitogen-activated protein kinase 14, a serine-thre-
onine kinase and central activator of non-canonical NF-κB 
signaling (7). In addition, a frequent aberration associated with 
BIRC3 is the recurrent t(11;18)(q21;q21) translocation, which 
involves the mucosa-associated lymphoid tissue lymphoma 
translocation gene 1 (MALT1), located on 18q21.32. This type 
of alteration appears in mucosa-associated lymphoid tissue 
(MALT) lymphoma (15).
The present study regarding BIRC3 copy number varia-
tions in 117 CLL and 45 B-ALL patients has revealed several 
major findings that, to the best of our knowledge, have not 
been previously reported. Firstly, BIRC3 duplications were 
detected in 3 cases of CLL, and 2 of these were associated 
with ATM and MALT1 duplications, in addition to TP53 dele-
tions; BIRC3 amplification was detected in these 2 cases as 
a result of a hyperdiploid cell clone and has been previously 
reported in cases of CLL, but is not a frequent event (16,17). In 
addition, 1 B-ALL patient possessed a duplication of BIRC3 
due to partial hyperdiploidy, which is more common in B-ALL 
compared with CLL, and is associated with good prognosis in 
pediatric patients (18). A CLL-case with a BIRC3 duplication 
possessed normal ATM and TP53 copy numbers; however, the 
duplication was not detected by aCGH, most likely due to the 
low sensitivity of aCGH for mosaic detection, despite being 
present in 36% of the cells. Previous studies on the interac-
tion of BIRC3 with the NF-κB pathway indicate that BIRC3 
duplication may lead to the inactivation of tumor suppressor 
activity (19-21).
As the predominant morphological feature of CLL is the 
accumulation of small B lymphocytes (1), B-ALL patients were 
chosen to be the second group to be tested for BIRC3-alterations 
in the present study. Therefore the second important finding of 
the present study is the detection of a BIRC3 deletion in 1 of the 
45 studied B-ALL cases. The aCGH for case A-1 revealed the 
deletion of almost all of the long arm of chromosome 11, and 
the most frequent aberrations associated with chromosome 11 
in B-ALL patients are structural abnormalities in band 11q23, 
which harbors the myeloid/lymphoid leukemia gene (22).
Chromosomal deletions involving 11q have been reported 
in certain subtypes of hematological malignancies, including 
B-cell CLL, and are associated with a poor prognosis in mantle 
cell lymphomas or T-cell prolymphocytic leukemia (23). 
Therefore, the prognosis for the B-ALL patient in the present 
study may be poor or extremely poor. Additional studies are 
required to determine the role of BIRC3 in the prognosis of 
B-ALL patients.
The disruption of BIRC3 is specifically restricted to 
chemo-refractory cases in progressive CLL patients, and may 
selectively associate with fludarabine‑refractory patients with 
normal TP53 (7). Therefore, another notable finding of the 
present study is that BIRC3 abnormalities were associated with 
TP53 deletion in only 4/117 CLL cases. According to previous 
studies, the frequency of BIRC3 disruption is low at diagnosis; 
however, BIRC3 disruptions tend to accumulate among refrac-
tory CLL and emerge over time. Patients harboring a BIRC3 
disruption typically experience an aggressive disease course, 
even compared with other clinically aggressive groups (14,24). 
This aspect of the disease was not the focus of the present 
study. However, examining BIRC3 duplication cases for the 
presence of mutations may be interesting for future study.
The application of a BIRC3 probe in iFISH increased the 
diagnostic yield in CLL and ALL cases. As in MLPA or aCGH 
by BIRC3-directed iFISH, only gain or loss of copy numbers 
can be registered. However, to the best of our knowledge, 
BIRC3 activation by a translocation has not previously been 
Figure 3. Results obtained for B-ALL case A-1 by array comparative genomic hybridization and iFISH are summarized. (A) Deletion in 11q22-q23, initially 
detected by iFISH, resulted in loss of the whole long arm of a chromosome 11. (B) Examples for heterozygote deletions of ATM and BIRC3 detected by iFISH 
are depicted. iFISH, interphase fluorescence in situ hybridization; ATM, ataxia telangiectasia mutated; BIRC3, baculoviral IAP repeat-containing 3; MALT1, 
mucosa-associated lymphoid tissue lymphoma translocation gene 1; D11Z1, CEP 11 probe.
  A   B
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reported. Therefore, routine iFISH and MLPA testing in 
CLL and ALL should be enhanced by a probe specific for 
BIRC3. iFISH is superior to MLPA as it is able to detect low 
level mosaics in the probe sample, however, MLPA is more 
cost-effective (2). A combination of the two approaches, by 
performing MLPA followed by iFISH in selected cases may 
be the best compromise if corresponding MLPA sets are avail-
able (2).
In conclusion, the hypothesis by Rose-Zerilli et al (25) 
that BIRC3 deletions are always associated with ATM dele-
tions is questioned at least for a small percentage of cases. As 
screening of the BIRC3 gene is not routinely undertaken for 
CLL patients (2,26), the results of the present study suggest 
that screening may be considered as necessary in the future, 
particularly to aid in making the correct treatment decisions; 
particularly, whether to treat with or without fludarabine.
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